Invited review-neuroimaging response assessment criteria for brain tumors in veterinary patients

Veterinary Radiology and Ultrasound

Volumn 55, Issue 2, 2014, Pages 115-132

  Rossmeisl, John H ^a,b   Garcia, Paulo A ^b   Daniel, Gregory B ^a   Bourland, John Daniel ^c   Debinski, Waldemar ^c   Dervisis, Nikolaos ^a   Klahn, Shawna ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b VA Polytechnic Institute and State University   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; MRI; Neurology; Oncology

Indexed keywords

ANIMAL; ANIMAL DISEASE; BRAIN TUMOR; DOG; DOG DISEASE; NEUROIMAGING; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW; SCINTIGRAPHY; STANDARD;

BRAIN TUMOR; MRI; NEUROLOGY; ONCOLOGY;

ANIMALS; BRAIN NEOPLASMS; DOG DISEASES; DOGS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEUROIMAGING; OUTCOME ASSESSMENT (HEALTH CARE); PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC;

EID: 84896706170     PISSN: 10588183     EISSN: 17408261     Source Type: Journal    
DOI: 10.1111/vru.12118     Document Type: Review

References (91)

1. Whelan HT, Clanton JA, Wilson RE, et al. Comparison of CT and MRI brain tumor imaging using a canine glioma model. Pediatr Neurol 1988;4:279-283.
2. Young BD, Levine JM, Porter BF, et al. Magnetic resonance imaging features of intracranial astrocytomas and oligodendrogliomas in dogs. Vet Radiol Ultrasound 2011;52:132-141.
3. Wisner ER, Dickinson PJ, Higgins RJ. Magnetic resonance imaging features of canine intracranial neoplasia. Vet Radiol Ultrasound 2011;52:S52-S61.
4. Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol 2011;84:S82-S89.
5. Bruzzone MG, D'Incerti L, Farina LL, et al. CT and MRI of brain tumors. Q J Nucl Med Mol Imaging 2012;56:112-137.
6. Giroux A, Jones JC, Bohn JH, et al. A new device for CT-guided stereotactic biopsy of the canine brain: design, construction and neelde placement accuracy. Vet Radiol Ultrasound 2002;43:229-236.
7. Moissonnier P, Blot S, Devauchelle P, et al. Steretotactic CT-guided brain biopsy in the dog. J Sm Anim Pract 2002;43:115-123.
8. Kimmelman J, Nalbantoglu J. Faithful companions: a proposal for neurooncology trials in pet dogs. Cancer Res 2007;67:4541-4544.
9. Rossmeisl JH, Robertson JL, Zimmerman KL, et al. Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas. Vet Comp Oncol 2009;7:173-180.
10. Higgins RJ, Dickinson PJ, LeCouteur RA, et al. Spontaneous canine gliomas: overexpression of EGFR, PDGFR alpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol 2010;98:49-55.
11. Thomas R, Shannon D, Wang H, et al. 'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol 2009;94:333-349.
12. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol 2010;12:928-940.
13. Ellis TL, Garcia PA, Rossmeisl JH, et al. Nonthermal irreversible electroporation for intracranial surgical applications. J Neurosurg 2011;114:681-688.
14. Dervisis NG, Dominguez PA, Sarbu L. Efficacy of temozolamide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. J Am Med Vet Assoc 2007;231:563-569.
15. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990;8:12777-1280.
16. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29:419-424.
17. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep 2011;13:50-56.
18. Butowski N, Chang SM. Endpoints for clinical trials and revised assessment in neurooncology. Curr Opin Neurol 2012;25:780-785.
19. Lutz K, Radbruch A, Wiestler B, et al. Neuroradiological response criteria for high-grade gliomas. Clin Neuroradiol 2011;21:199-205.
20. Pope WB, Sayre J, Perlina A, et al. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466-2474.
21. Heidner GL, Kornegay JN, Page RL, et al. Analysis of survival in a retrospective study of 86 dogs with brain tumors. J Vet Int Med 1991;5:219-226.
22. Doyle FH, Gore JC, Pennock JM, et al. Imaging of the brain by nuclear magnetic resonance. Lancet 1981;2:53-57.
23. Bilaniuk LT, Zimmerman RA, Wehrli FW, et al. Cerebral magnetic resonance: comparison of high and low filed strength imaging. Radiology 1984;153:409-414.
24. Mehta AI, Kanaly CW, Friedman AH, et al. Monitoring radiographic brain tumor progression. Toxins 2011;3:191-200.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors: European Organization or Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
26. Eisenhauer AE, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
27. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
28. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
29. Paoloni MC, Tandle A, Mazcko C, et al. Launching a novel pre-clinical infrastructure: comparative oncology trials consortium directed targeting of TNFalpha to cancer vasculature. PLoS One 2009;4:e4972.
30. Leblanc AK, Miller AN, Galyon GD, et al. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. Vet Radiol Ultrasound 2012;53:348-357.
31. Sturges BK, Dickinson PJ, Bollen AW, et al. Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 Dogs. J Vet Int Med 2008;22:586-585.
32. Sorenson AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19:551-557.
33. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol 2006;8:156-165.
34. Ellingson BM, Cloughesy TF, Lai A, et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neurol Oncol 2011;13:401-409.
35. Kanaly CW, Ding D, Mehta AI, et al. A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 2011;6:e16031.
36. Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001;93:1401-1405.
37. Cairncross JG, Macdonald DR, Pexman JH, et al. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724-726.
38. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-1889.
39. Konar M, Lang J. Pros and cons of low-field magnetic resonance imaging in veterinary practice. Vet Radiol Ultrasound 2011;52:S5-S14.
40. Matthews VP, Caldemeyer KS, Ulmer JL, et al. Effects of contrast dose, delayed imaging, anf magnetization transfersaturation on gadolinium-enhanced MR imaging of brain lesions. J Magn Reson Imaging 1997;7:14-22.
41. Chavhan GB, Babyn PS, Jankharia BG, et al. Steady-state MR imaging sequences: physics, classification, and clinical applications. Radiographics 2008;28:1147-1160.
42. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 2006;8:38-46.
43. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-888.
44. Lorenzon M, Zuiani C, Londero V, et al. Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool? Eur J Radiol 2009;71:82-88.
45. Forsyth PA, Petrov E, Mahallati H, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 1997;15:2076-2081.
46. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008;28:329-344.
47. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633-638.
48. Rossmeisl JH, Duncan RB, Huckle WR, et al. Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms. Am J Vet Res 2007;68:1239-1245.
49. Dickinson PJ, Sturges BK, Higgins RJ, et al. Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors. Vet Pathol 2008;45:131-139.
50. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180-188.
51. Smith MM, Thomson JE, Castillo M, et al. MR of recurrent high-grade astrocytoma after intralesional immunotherapy. AJNR Am J Neuroradiol 1996;17:1065-1071.
52. Matheus MG, Castillo M, et al. CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience. AJNR Am J Neuroradiol 2004;25:1211-1217.
53. Kumar AJ, Leeds NE, Fuller GN. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-384.
54. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006;111:197-212.
55. Garcia PA, Pancotto T, Rossmeisl JH, et al. Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol Cancer Res Treat 2011;10:73-83.
56. Fink J, Born D, Chamberlain, et al. Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors. Curr Neurol Neurosci Rep 2012;12:276-285.
57. Shenoy A. Clinical applications of imaging biomarkers. Part 3. The neuro-oncologist's perspective. Br J Radiol 2011;84:S209-S212.
58. Brodbelt A. Clinical applications of imaging biomarkers. Part 2. The neurosurgeon's perspective. Br J Radiol 2011;84:S205-S208.
59. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8:259-267.
60. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion mapas an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 2005;102:16759-16764.
61. Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26:3387-3394.
62. Ellingson BM, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 2011;102:95-103.
63. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-189.
64. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491-498.
65. Shah RS, Vattoth S, Jacobs R, et al. Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence. Radio Graphics 2012;32:1343-1359.
66. Peng SL, Chen CF, et al. Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy. NMR Biomed 2012; 26:443-450.
67. Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1505-1510.
68. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490-498.
69. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival inpatients with glioblastoma. Radiology 2010;256:575-584.
70. MacLeod AG, Dickinson PJ, LeCouteur RA, et al. Quantitative assessment of blood volume and permeability in cerebral mass lesions using dynamic contrast-enhanced computed tomography in the dog. Acad Radiol 2009;16:1187-1195.
71. Zhao Q, Lee S, Kent M, et al. Dynamic contrast-enhanced magnetic resonance imaging of canine brain tumors. Vet Radiol Ultrasound 2010;51:122-129.
72. Siu A, Wind JJ, et al. Radiation necrosis following treatment of high grade glioma-a review of the literature and current understanding. Acta Neurochir (Wien) 2012;154:191-201.
73. 99mTc-sodium pertechnetate in experimental cerebral lesions. J Nucl Med 1969;10:290-293.
74. Bok BD, Scheffel U, Goldfarb HW, et al. Comparison of 99Tcm complexes (NEP-DADT, ME-NEP-DADT, and HMPAO) with 123IAMP from brain SPECT imaging in dogs. Nucl Med Commun 1987;8:631-641.
75. Gomez-Rio M, Rodriguez-Fernandez A, Ramos-Font C, et al. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 2008;35:966-975.
76. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-750.
77. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39-51.
78. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumors. Radiother Oncol 2010; 96:325-327.
79. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-1958.
80. 18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 2013;3:341-351.
81. 18F-fluoroethyl)-l-tyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-1057.
82. 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36-44.
83. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am 2009;19:625-646.
84. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res 1999;59:6159-6163.
85. 18F-FDG. J Nucl Med 2005;46:945-952.
86. Vincentelli C, Hwang SN, Hlder CA, et al. The use of neuroimaging to guide the histologic diagnosis of central nervous system lesions. Adv Anat Pathol 2012;19:97-107.
87. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604-612.
88. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image- guided histopathology with special attention to radiation necrosis. Neurosurgery 2004;54:1111-1117.
89. Mikoloski KR, March PA, Faissler D. Diagnostic value and discriminatory ability of proton magnetic resonance spectroscopy for intracranial neoplasia in dogs. J Vet Int Med 2012;26:804(abstract N-7).
90. Chong VF, Rumpel H, Fan YF, et al. Temporal lobe changes following radiation therapy: imaging and proton MR spectroscopic findings. Eur Radiol 2001;11:317-324.
91. Schlemmer HP, Bachert P, Herfarth KK, et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 2001;22:1316-1324.